Litigation Details for Amgen Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Amgen Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-12-15 |
| Court | District Court, D. Delaware | Date Terminated | 2018-02-13 |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory Moneta Sleet |
| Jury Demand | None | Referred To | |
| Patents | 6,011,068; 6,031,003; 6,211,244; 6,313,146; 7,829,595; 9,375,405 | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Amgen Inc. v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Biologic Drugs cited in Amgen Inc. v. Teva Pharmaceuticals USA, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Amgen Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-12-14 | 1 | Complaint | Book lists U.S. Patent Nos. 6,011,068 (“the ’068 patent”), 6,031,003 (“the ’003 patent”), 6,313,146 (“… infringement of U.S. Patent No. 9,375,405 (the “’405 patent”) under the Patent Laws of the United States…(“the ’146 patent”), and previously listed U.S. Patent No. 6,211,244 (“the ’244 patent”) (collectively… THE PATENT-IN-SUIT 12. On June 28, 2016, the ’405 patent, titled “Rapid …United States Patent and Trademark Office (“PTO”). 13. The ’405 patent is assigned to | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
